Amylin is co-secreted with insulin by beta cells and signals satiety through the area postrema. Cagrilintide is a long-acting analog engineered for weekly administration, acting at amylin and calcitonin receptor complexes. Its interest lies in a satiety mechanism largely orthogonal to GLP-1, which is why it is being developed in combination with semaglutide (CagriSema).
Phase 2 established weight effects as monotherapy and in combination. Phase 3 combination programmes are ongoing and have reported mixed results against expectations. Not established.
Not approved. Investigational.
Under investigation. Gastrointestinal effects reported in trials. Human safety not established.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.